MA27184A1 - Dosage d'anticorps anti-ingap - Google Patents

Dosage d'anticorps anti-ingap

Info

Publication number
MA27184A1
MA27184A1 MA27843A MA27843A MA27184A1 MA 27184 A1 MA27184 A1 MA 27184A1 MA 27843 A MA27843 A MA 27843A MA 27843 A MA27843 A MA 27843A MA 27184 A1 MA27184 A1 MA 27184A1
Authority
MA
Morocco
Prior art keywords
ingap
antibody assay
antibody
assay
ingap antibody
Prior art date
Application number
MA27843A
Other languages
English (en)
Inventor
Aaron I Vinik
David A Taylor-Fishwick
Original Assignee
Gmp Endotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gmp Endotherapeutics Inc filed Critical Gmp Endotherapeutics Inc
Publication of MA27184A1 publication Critical patent/MA27184A1/fr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4733Acute pancreatitis-associated protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/474Pancreatic thread protein; Reg protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA27843A 2002-03-01 2004-08-31 Dosage d'anticorps anti-ingap MA27184A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36104002P 2002-03-01 2002-03-01

Publications (1)

Publication Number Publication Date
MA27184A1 true MA27184A1 (fr) 2005-01-03

Family

ID=27789061

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27843A MA27184A1 (fr) 2002-03-01 2004-08-31 Dosage d'anticorps anti-ingap

Country Status (17)

Country Link
US (2) US7166439B2 (fr)
EP (1) EP1478923A4 (fr)
JP (1) JP2005519276A (fr)
KR (1) KR20040105738A (fr)
CN (1) CN1639572A (fr)
AU (1) AU2003216469A1 (fr)
BR (1) BR0308095A (fr)
CA (1) CA2476979A1 (fr)
CO (1) CO5611199A2 (fr)
IL (1) IL163580A0 (fr)
MA (1) MA27184A1 (fr)
MX (1) MXPA04008430A (fr)
NO (1) NO20044145L (fr)
PL (1) PL373569A1 (fr)
RU (1) RU2004129314A (fr)
WO (1) WO2003074549A2 (fr)
ZA (1) ZA200406877B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
EP1858545A2 (fr) * 2005-03-04 2007-11-28 Curedm Inc. Methodes et compositions pharmaceutiques pour traiter des diabetes sucres de type 1 et d'autres troubles
EP1883417A2 (fr) 2005-05-25 2008-02-06 Curedm Inc. Peptides, derives et analogues associes, et leurs methodes d'utilisation
US8785400B2 (en) * 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
DK2193142T3 (da) * 2007-08-30 2015-04-20 Curedm Group Holdings Llc Præparater og fremgangsmåder til anvendelse af pro-øcellepeptider og analoger dertil
US20110082080A1 (en) * 2007-10-12 2011-04-07 Curedm Group Holdings, Llc Compositions and methods of using the human proislet peptide receptor
US20090288960A1 (en) * 2008-02-12 2009-11-26 Robert Rubin Rapid Detection of Anti-Chromatin Autoantibodies in Human Serum using a Portable Electrochemical Biosensor
US20160039877A1 (en) 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2100883A1 (fr) * 1991-11-25 1993-05-26 Dade International Inc. Dosage immunologique a l'aide de peptides synthetiques du htlv-ii
CA2213610C (fr) * 1995-02-22 2013-12-03 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Proteine ingap impliquee dans la neogenese des ilots pancreatiques
US5834590A (en) * 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
KR20000052972A (ko) * 1996-10-31 2000-08-25 윌리암 로엘프 드 보에르 유전성의 방사선경화 코팅 조성물 및 상기 코팅재로 피복된 금속 전도체
US6986994B2 (en) * 2001-01-09 2006-01-17 Gmp Endotherapeutics, Inc. INGAP displacement assays

Also Published As

Publication number Publication date
US20070184504A1 (en) 2007-08-09
CO5611199A2 (es) 2006-02-28
MXPA04008430A (es) 2004-11-26
US7166439B2 (en) 2007-01-23
CA2476979A1 (fr) 2003-09-12
US20030166031A1 (en) 2003-09-04
CN1639572A (zh) 2005-07-13
WO2003074549A2 (fr) 2003-09-12
IL163580A0 (en) 2005-12-18
JP2005519276A (ja) 2005-06-30
EP1478923A2 (fr) 2004-11-24
AU2003216469A1 (en) 2003-09-16
WO2003074549A3 (fr) 2003-12-18
KR20040105738A (ko) 2004-12-16
ZA200406877B (en) 2005-04-08
RU2004129314A (ru) 2005-04-20
NO20044145L (no) 2004-11-30
PL373569A1 (en) 2005-09-05
BR0308095A (pt) 2006-01-17
EP1478923A4 (fr) 2005-09-21

Similar Documents

Publication Publication Date Title
EP1423431A4 (fr) Anticorps anti-vla-1
EP1396500A4 (fr) Anticorps anti-trail-r
MA29014B1 (fr) Formulations d'anticorps
FR10C0050I2 (fr) Anticorps opgl
EP1378520A4 (fr) Anticorps trispecifique monocatenaire cyclique
EP1766017A4 (fr) Anticorps specifique d'une tumeur
EP1616881A4 (fr) Anticorps anti-mpl
DE60115698D1 (de) Medikamentenspender
EP1542721A4 (fr) Anticorps "s" modifies
DE60131662D1 (de) Assayvorrichtung
EP1490110A4 (fr) Anticorps anti-alpha v beta 6
EP1327681A4 (fr) Anticorps agoniste degrade
EP1535930A4 (fr) Anticorps specifique a une proteine-tetra centrale
DE60003606D1 (de) Immunochromatographisches Assay
IS6779A (is) Mannlíkt mótefni gegn LT-beta-R
EP1463522A4 (fr) Anticorps anti-pneumocoques humains provenant d'animaux non humains
EP1390741A4 (fr) Construction structurelle de bibliotheques d'anticorps humains
EE05020B1 (et) Glburiidi ravimkoostis
EP1680666A4 (fr) Detection d'anticorps anti-therapeutique humain
ATE285753T1 (de) Lysin enthaltende kautablette
EP1178829A4 (fr) Anticorps monoclonal humain
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
EP1381349A4 (fr) Dosage de tyrosinase
EP1335024A4 (fr) Anticorps inhibant l'activite vplf
EP1293850A4 (fr) Processeur d'information